Combination of | |
---|---|
Dapagliflozin | SGLT-2 inhibitor |
Saxagliptin | Dipeptidyl peptidase-4 inhibitor |
Clinical data | |
Trade names | Qtern |
AHFS/Drugs.com | Professional Drug Facts |
License data | |
Pregnancy category |
|
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
CAS Number | |
KEGG |
Dapagliflozin/saxagliptin, sold under the brand name Qtern, is a fixed-dose combination anti-diabetic medication used as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.[2][3] It is a combination of dapagliflozin and saxagliptin.[2][3] It is taken by mouth.[2][3]
The most common side effects include upper respiratory tract infection (such as nose and throat infections) and, when used with a sulphonylurea, hypoglycaemia (low blood glucose levels).[3]
Dapagliflozin/saxagliptin was approved for medical use in the European Union in July 2016, and in the United States in February 2017.[3][4]
In the United States dapagliflozin/saxagliptin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.[2]
In the European Union it is indicated in adults aged 18 years and older with type 2 diabetes mellitus: